Roche Holding AG (XTER:RHO) Beneish M-Score: -2.70 (As of Jun. 26, 2026)


XTER:RHO Roche Holding AG XTER:RHO
79 GF Score
Price €373.20
GF Value €296.02
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Roche Holding AG Beneish M-Score?

Roche Holding AG XTER:RHO +1.36% 79 Beneish M-Score is -2.70 as of Jun. 26, 2026. GuruFocus rates XTER:RHO with a GF Score™ of 79/100 and a GF Value™ of €296.02 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Roche Holding AG ranks better than 68.17% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.7 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Roche Holding AG's Beneish M-Score or its related term are showing as below:

XTER:RHO' s Beneish M-Score Range Over the Past 10 Years
Min: -3.05   Med: -2.8   Max: -2.7
Current: -2.7

During the past 13 years, the highest Beneish M-Score of Roche Holding AG was -2.70. The lowest was -3.05. And the median was -2.80.


Roche Holding AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Beneish M-Score Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.82 -2.73 -2.77 -3.00 -2.70

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.77 0.00 -3.00 0.00 -2.70

XTER:RHO vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Beneish M-Score falls into.


XTER:RHO
79GF Score
Roche Holding AG XTER:RHO
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Roche Holding AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0267+0.528 * 1.0024+0.404 * 1.0379+0.892 * 1.0159+0.115 * 0.9796
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0024+4.679 * -0.059303-0.327 * 0.9691
=-2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €15,097 Mil.
Revenue was €67,896 Mil.
Gross Profit was €50,058 Mil.
Total Current Assets was €41,504 Mil.
Total Assets was €107,919 Mil.
Property, Plant and Equipment(Net PPE) was €24,577 Mil.
Depreciation, Depletion and Amortization(DDA) was €3,629 Mil.
Selling, General, & Admin. Expense(SGA) was €16,247 Mil.
Total Current Liabilities was €30,007 Mil.
Long-Term Debt & Capital Lease Obligation was €30,729 Mil.
Net Income was €13,803 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €20,203 Mil.
Total Receivables was €14,475 Mil.
Revenue was €66,832 Mil.
Gross Profit was €49,391 Mil.
Total Current Assets was €42,883 Mil.
Total Assets was €109,040 Mil.
Property, Plant and Equipment(Net PPE) was €25,428 Mil.
Depreciation, Depletion and Amortization(DDA) was €3,666 Mil.
Selling, General, & Admin. Expense(SGA) was €15,955 Mil.
Total Current Liabilities was €28,945 Mil.
Long-Term Debt & Capital Lease Obligation was €34,379 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(15097.443 / 67895.626) / (14474.955 / 66831.791)
=0.222363 / 0.216588
=1.0267

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(49390.938 / 66831.791) / (50057.967 / 67895.626)
=0.739034 / 0.737278
=1.0024

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (41504.036 + 24577.282) / 107918.637) / (1 - (42882.885 + 25428.107) / 109039.878)
=0.387675 / 0.373523
=1.0379

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=67895.626 / 66831.791
=1.0159

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3666.403 / (3666.403 + 25428.107)) / (3628.616 / (3628.616 + 24577.282))
=0.126017 / 0.128647
=0.9796

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(16247.326 / 67895.626) / (15955.227 / 66831.791)
=0.239299 / 0.238737
=1.0024

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((30728.568 + 30007.346) / 107918.637) / ((34379.357 + 28944.555) / 109039.878)
=0.562794 / 0.580741
=0.9691

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(13802.886 - 0 - 20202.796) / 107918.637
=-0.059303

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Roche Holding AG has a M-score of -2.69 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.70 mean?
Roche Holding AG (XTER:RHO) has a Beneish M-Score of -2.70 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Roche Holding AG and its competitors. According to the industry distribution chart, Roche Holding AG ranks #290 out of 911 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Roche Holding AG's Beneish M-Score too high?
Roche Holding AG's current Beneish M-Score is -2.70. Based on the distribution chart, Roche Holding AG ranks #290 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #290 out of 911 companies for Beneish M-Score. This puts Roche Holding AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Beneish M-Score is -2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XTER:RHO) is currently considered Modestly Overvalued. The stock's GF Value™ is €296.02, compared to a current price of €373.20 — trading 26.1% above its estimated fair value. The current Beneish M-Score is -2.70. Roche Holding AG's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Roche Holding AG (XTER:RHO), the current Beneish M-Score is -2.70 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XTER:RHO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €373.20 is trading 26.1% above its estimated GF Value™ of €296.02. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XTER:RHO:

  • Beneish M-Score: -2.70
  • GF Value™: €296.02 vs. price of €373.20 (26.1% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the XTER:RHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score

Get the complete analysis for XTER:RHO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€373.20
Price
€296.02
GF Value